EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Hua Medicine (2552) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Hua Medicine HK$5.88, price HK$2.35, upside +150.8%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · HK · Based in China · ISIN KYG4644K1022

HM Thin data Oct 4, 2026

Hua Medicine

2552 · HK

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

Fair value HK$5.88 · Strongly undervalued (+150.8%)
Low debt
Ranks above peers (7/10)
Quality 57/100
Mixed Growth (revenue 5y +123.2 %/yr in HKD)
Negative free cash flow
Narrow moat 33/100
Thin data
Watch Hua Medicine for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$5.31 HK$1.08 Fair Value HK$5.88 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.

How to read this chart

60‑month range HK$1.08 – HK$5.31 · fair‑value band HK$3.89 – HK$15.17 · the HK$2.35 price screens below the HK$5.88 fair value. Dashed = 300-day average. As of Oct 4, 2026.

Follow Hua Medicine in your weekly email

Every Wednesday you see whether Hua Medicine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD.

Show more

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.

Stock analysis

Hua Medicine (2552) currently trades at HK$2.35, while our model-based Fair Value estimate is HK$5.88, implying the stock looks roughly 60.1% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$58.72 per share, and 8 of the 10 models we run sit above the HK$2.35 price.

Bear case: the Asset-Based group reads lowest at HK$0.7900, and 2 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$3.89 (bear) to HK$15.17 (bull), the price of HK$2.35 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Hua Medicine reported revenue of 480M CNY in FY2025 versus 0 CNY in FY2021. Reported net income was 1.1B CNY in FY2025.

Key figures

Market cap HK$2.4B (≈ $300M) · P/E ratio 1.9 · P/S ratio 4.17 · EPS (TTM) HK$1.19 · Net margin 224% · Return on equity 254% · Return on assets (EBIT) −21.8% · Operating margin −28.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (medium confidence).

What moves the price

The share trades about 52% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 151%, 2552 screens cheaper than that median.

Fair Value models

Bear HK$3.89 Fair Value HK$5.88 Bull HK$15.17
Price HK$2.35 · Upside +150.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.9064 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings HK$15.49 HK$29.44 HK$53.79 71
Growth-Adj P/E HK$41.11 HK$58.72 HK$76.34 65
P/E Multiple HK$20.85 HK$27.81 HK$34.76 63
All 10 models by family
DCF Models
Owner Earnings HK$15.49 HK$29.44 HK$53.79 71
Earnings-Based
Graham-Dodd HK$8.59 HK$59.94 HK$84.11 61
Lynch FV HK$30.97 HK$44.24 HK$57.51 59
PEG = 1.0 HK$30.97 HK$44.24 HK$57.51 55
Multiples
P/E Multiple HK$20.85 HK$27.81 HK$34.76 63
P/S Multiple HK$1.48 HK$1.97 HK$2.46 58
P/B Multiple HK$3.99 HK$5.31 HK$6.64 55
Asset-Based
NCAV (Graham) HK$0.5900 HK$0.7900 HK$1.18 54
Economic Profit
Residual Income HK$3.48 HK$5.94 HK$15.41 59
Growth Earnings
Growth-Adj P/E HK$41.11 HK$58.72 HK$76.34 65

Open the full fair value analysis →

Notify me when 2552 reaches fair value

Put 2552 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 57/100

Of which business quality 57 · Market factors (momentum, volatility) 20

Profitability 70
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 72
Balance sheet, leverage, solvency risk
Investment 51
Disciplined investing over empire-building
Low Volatility 42
Calm price path (market factor)
Momentum 12
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 64
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+87.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+201.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+123.2%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+110.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,067.2% (2020) → −29.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch 2552, get fair value alerts →

Compare Hua Medicine with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks

Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside +150.7% · Top 25%
Profitability
Return on equity (TTM) 254.1% · Top 25%
Return on assets −6.0% · Bottom 25%
Operating margin (TTM) −28.9% · Bottom 25%
Growth and dividend
Revenue growth 79.8% · Top 25%
Balance sheet
Debt / equity 0.22× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 1.9× · Cheapest 25%
P/B 0.30× · Cheapest 25%
P/S (TTM) 0.61× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 17
FUTURE (revenue growth)100 · sector 24
PAST (return on equity)100 · sector 26
HEALTH (low debt)89 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $17.86 $11.35 −36%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hua Medicine · Fair Value
HK$5.88 +60%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Hua Medicine Fair Value". https://www.fairvalue-calculator.com/stock/2552

Frequently asked questions

Is Hua Medicine (2552) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of HK$5.88 versus a price of HK$2.35, about +151% upside (undervalued).
What is the fair value of 2552?
Our model-based fair value for Hua Medicine is HK$5.88 (as of Oct 4, 2026), built from audited fundamentals. The current price: HK$2.35.
What is the quality score of 2552?
Hua Medicine has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hua Medicine (2552)?
Our model-based price target is the fair value of HK$5.88 (as of Oct 4, 2026) from 10 valuation models. Cautious scenario HK$3.89, optimistic scenario HK$15.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Hua Medicine stock forecast for 2026?
Our models put fair value at HK$5.88, about +151% upside versus a price of HK$2.35 (undervalued). Cautious scenario HK$3.89, optimistic scenario HK$15.17. The calculation is refreshed regularly with new filings.
What is the revenue of Hua Medicine (2552)?
Hua Medicine reported trailing-twelve-month revenue of about HK$493M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Hua Medicine (2552)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hua Medicine it is HK$5.88 per share (as of Oct 4, 2026), against a price of HK$2.35. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Hua Medicine stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 2552 trades below its calculated fair value: price HK$2.35, fair value HK$5.88, a gap of about +151% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2552?
No. The price is what the market pays today (HK$2.35); the fair value is what the company's own numbers justify (HK$5.88). For Hua Medicine the two are HK$3.54 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hua Medicine worth?
The market values Hua Medicine at about HK$2.4B (market capitalisation, as of Oct 4, 2026). Per share that is HK$2.35; our models calculate a fair value of HK$5.88 per share.
What do the bullish and bearish scenarios say about 2552?
Our models span a range for Hua Medicine: cautious scenario HK$3.89, base HK$5.88, optimistic HK$15.17 per share (as of Oct 4, 2026, price HK$2.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2552?
Hua Medicine trades at a price-to-earnings ratio of 1.9 (as of Oct 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$5.88 is built from several models across several years. Other multiples: P/B 0.3, P/S 0.6.
How solid is the balance sheet of Hua Medicine (2552)?
Balance-sheet figures for Hua Medicine (as of Oct 4, 2026): return on equity 254.1%, debt of 0.22 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 2552 from its 52-week high?
Hua Medicine trades at HK$2.35, about 52% below its 52-week high of HK$4.86 and 18% above the low of HK$1.99 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of HK$5.88 is for.
Which stocks are comparable to Hua Medicine?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hua Medicine stock attractive at the current price?
The data as of Oct 4, 2026: price HK$2.35, calculated fair value HK$5.88 (+151%), Quality Score 57/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2552 calculated?
We run Hua Medicine through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$5.88, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Hua Medicine currently trades 60 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hua Medicine (2552)?
The closing price on Oct 2, 2026 was HK$2.35. Our model-based fair value is HK$5.88, about +151% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hua Medicine right now?
The price is below even our cautious bear case (HK$3.89). The market is more pessimistic than our downside scenario. The model range is unusually wide (HK$3.89 to HK$15.17). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Hua Medicine

How large is the market capitalisation of Hua Medicine (2552)?
The market capitalisation of Hua Medicine is HK$2.4B (≈ $300M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hua Medicine (2552)?
The price-to-sales ratio of Hua Medicine is 4.17 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hua Medicine (2552)?
Earnings per share at Hua Medicine are HK$1.19 (price ÷ EPS = P/E 1.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hua Medicine (2552)?
The net margin of Hua Medicine is 224% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hua Medicine (2552)?
The return on equity (ROE) of Hua Medicine is 254% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hua Medicine (2552)?
On an EBIT basis the return on assets of Hua Medicine is −21.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hua Medicine (2552)?
The operating margin of Hua Medicine is −28.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hua Medicine (2552)?
Revenue at Hua Medicine is growing +79.8% versus a year earlier (3y avg +201%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hua Medicine (2552) generate?
The free cash flow of Hua Medicine is −HK$59.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Hua Medicine (2552) hold?
Hua Medicine holds more cash than debt, HK$791M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Hua Medicine in the live analysis

One click puts Hua Medicine on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.